Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Core Insights - Mineralys Therapeutics' shares increased by 4.4% following the FDA's acceptance of the new drug application (NDA) for lorundrostat, aimed at treating adult patients with hypertension in conjunction with other antihypertensive medications. A final decision from the FDA is anticipated by December 22, 2026 [1][8]. Company Developments - If approved, lorundrostat could offer a new treatment option for patients suffering from resistant and uncontrolled hypertension, based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction [2][9]. - The NDA acceptance coincided with the release of top-line data from the phase II Explore-OSA study, which assessed lorundrostat for treating overweight or obese adults with moderate-to-severe obstructive sleep apnea (OSA) and hypertension [6][8]. - The Explore-OSA study indicated that four weeks of treatment with lorundrostat (50 mg) did not show a clinically meaningful difference in the apnea-hypopnea index (AHI) compared to placebo, the primary endpoint of the study. However, it did show a significant reduction in blood pressure and favorable safety [7][9]. Clinical Study Outcomes - Previous pivotal studies, including the phase III Launch-HTN and phase II Advance-HTN studies, demonstrated that lorundrostat met its primary efficacy endpoints with statistical significance and exhibited favorable safety and tolerability in patients with uncontrolled or resistant hypertension [10]. - Additionally, positive top-line data from the phase II Explore-CKD study indicated that lorundrostat, when added to an SGLT2 inhibitor, significantly improved outcomes in hypertensive patients with chronic kidney disease (CKD) [10]. Market Performance - Despite the recent positive news, Mineralys' shares have declined by 21.6% year-to-date, contrasting with a 6.1% increase in the industry [5]. - Currently, Mineralys has no approved products in its portfolio, making a potential FDA approval for lorundrostat a significant milestone for the company [11].